D. E. Shaw & Co., Inc. Tg Therapeutics, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $100 Billion
- Q1 2025
A detailed history of D. E. Shaw & Co., Inc. transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 62,500 shares of TGTX stock, worth $2.46 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
62,500
Previous 55,900
11.81%
Holding current value
$2.46 Million
Previous $1.68 Million
46.49%
% of portfolio
0.0%
Previous 0.0%
Shares
31 transactions
Others Institutions Holding TGTX
# of Institutions
416Shares Held
88.1MCall Options Held
2.34MPut Options Held
1.94M-
Vanguard Group Inc Valley Forge, PA15.6MShares$613 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$448 Million0.0% of portfolio
-
State Street Corp Boston, MA7.43MShares$292 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA3.28MShares$129 Million0.01% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.85MShares$112 Million9.29% of portfolio
About TG THERAPEUTICS, INC.
- Ticker TGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 145,274,000
- Market Cap $5.71B
- Description
- TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...